CHAPTER 1 INTRODUCTION
1.1. Market Definition
1.2. Executive Summary
1.3. The Scope of the Study
CHAPTER 2 RESEARCH METHODOLOGY
2.1. Secondary Research
2.2. Primary Research
2.3. Analytic Tools and Model
2.4. Economic Indicator
2.4.1. Base Year, Base Currency, Forecasting Period
2.5. Expert Validation
2.6. Study Timeline
CHAPTER 3 MARKET ANALYSIS
3.1. Industry Value Chain Analysis
3.2. Porter's Five Force Analysis
3.2.1. Bargaining Power of Buyers
3.2.2. Bargaining Power of Suppliers
3.2.3. Threats of Substitutes
3.2.4. Threats of New Entrants
3.2.5. Degree of Competition
3.3. PESTLE Analysis
3.3.1. Political
3.3.2. Economical
3.3.3. Social
3.3.4. Technological
3.3.5. Legal
3.3.6. Environmental
3.4. SWOT Analysis
3.4.1. Strengths
3.4.2. Weakness
3.4.3. Opportunities
3.4.4. Threats
3.5. Y-O-Y Analysis
CHAPTER 4 MARKET DYNAMICS
4.1. Market Drivers & Opportunities
4.1.1. Rising attention on geriatric and pediatric patients coupled with growth in the biologics
4.1.2. Growing incidence of chronic diseases and transformation of lifestyle owing to
urbanisation
4.1.3. The growing need for minimum invasive surgeries and launch of novel products
4.1.4. Rising demand for biosimilar and generic drugs and self-administration & home care
4.1.5. Focus on overcoming unmet medical needs & emerging market
4.2. Market Restraints & Challenges
4.2.1. Pricing pressure, patent expiry and the patent cliff
4.2.2. Product recalls, the risk of needle stick injuries and side effects of drugs
CHAPTER 5 GLOBAL DRUG DELIVERY TECHNOLOGIES MARKET – BY ROUTE
OF ADMINISTRATION
5.1. Transdermal Route
5.2. Nasal Drug Delivery
5.3. Inhalation Route
5.4. Oral Route
5.5. Parenteral Route
5.5.1. Intra-arterial
5.5.2. Subcutaneous route
5.5.3. Intramuscular
5.5.4. Intravenous
5.6. Others
CHAPTER 6 GLOBAL DRUG DELIVERY TECHNOLOGIES MARKET – BY END
USER
6.1. Diagnostic Centres
6.2. Home care settings
6.3. Hospitals & Clinics
6.4. Others
CHAPTER 7 GLOBAL DRUG DELIVERY TECHNOLOGIES MARKET – BY
GEOGRAPHY
7.1. Introduction
7.2. North America
7.2.1. U.S.
7.2.2. Canada
7.2.3. Mexico
7.2.4. Costa Rica
7.3. South America
7.3.1. Brazil
7.3.2. Argentina
7.3.3. Chile
7.3.4. Columbia
7.3.5. Others
7.4. Europe
7.4.1. U.K.
7.4.2. Germany
7.4.3. France
7.4.4. Italy
7.4.5. Spain
7.4.6. Russia
7.4.7. Netherlands
7.4.8. Switzerland
7.4.9. Poland
7.4.10. Others
7.5. APAC
7.5.1. China
7.5.2. Japan
7.5.3. India
7.5.4. South Korea
7.5.5. Australia & New Zealand
7.5.6. Malaysia
7.5.7. Singapore
7.5.8. Others
7.6. Middle East & Africa
7.6.1. UAE
7.6.2. Saudi Arabia
7.6.3. Iran
7.6.4. Iraq
7.6.5. Qatar
7.6.6. South Africa
7.6.7. Algeria
7.6.8. Morocco
7.6.9. Nigeria
7.6.10. Egypt
7.6.11. Others
CHAPTER 8 GLOBAL DRUG DELIVERY TECHNOLOGIES MARKET - COMPANY
PROFILES
8.1. Bayer AG
8.2. Antares Pharma, Inc.
8.3. Becton, Dickinson and Company
8.4. Sanofi S.A.
8.5. Merck & Co., Inc.
8.6. The 3M Company
8.7. GlaxoSmithKline PLC
8.8. Johnson & Johnson, Inc.
8.9. Novartis AG
8.10. Pfizer, Inc.
8.11. F. Hoffmann-La Roche Ltd.
CHAPTER 9 GLOBAL DRUG DELIVERY TECHNOLOGIES MARKET –
COMPETITIVE LANDSCAPE
9.1. Market Share Analysis
9.2. Strategies adopted by top companies
9.3. Mergers, Acquisitions, Collaborations & Agreements
CHAPTER 10 MARKET INSIGHTS
10.1. Industry Experts Insights
10.2. Analysts Opinions
10.3. Investment Opportunities
CHAPTER 11 APPENDIX
11.1. List of Tables
11.2. List of Figures
